BPC-157
Also known as: Body Protection Compound, PL 14736
Synthetic pentadecapeptide discussed in the biohacking and rehab space mainly for its possible tissue- and gut-protective effects.
Substance family
Peptides used for tendon, gut and skin repair. Mechanisms are described and animal data exists; controlled human trials for these applications largely do not.
Effects on
Which outcomes this substance acts on — descriptive, not a recommendation.
Strain profile
Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.
This substance works against
Dosing & protocols by goal
Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.
Tendons / ligaments / joints
RegenerationDose
250–500 µg / day
Frequency
1–2× / day (subcutaneous, possibly near the affected area)
Cycle length
4–6 weeks
User reports, no robust human studies. Dose in µg, not mg.
Gut health
RegenerationDose
250–500 µg / day
Frequency
1–2× / day (oral common)
Cycle length
4–8 weeks
For a gastrointestinal focus, oral administration is often preferred.
Side effect & countermeasure
Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.
Problem
Unclear long-term safety in humans
Countermeasure
Dose conservatively, short cycles; clarify medically with pre-existing conditions (especially cancer risk).
Problem
Product quality / purity uncertain on the gray market
Countermeasure
Only vendors with an independent analysis certificate (HPLC/MS); reconstitute sterile and store refrigerated.
Overview
BPC-157 ("Body Protection Compound-157") is a synthetic peptide of 15 amino acids, originally derived from a protein found in gastric juice. In the biohacking and rehab scene, it is discussed mainly in connection with tendon, ligament and gut problems.
Mechanism of Action
Preclinical studies (predominantly animal and cell models) point to angiogenic effects (promotion of new blood-vessel formation) as well as possible modulation of growth factors involved in tissue regeneration. Controlled clinical studies in humans are still largely lacking — a large part of the circulating efficacy claims rests on animal models, anecdotal reports and a young field of research.
Typical Context
BPC-157 is discussed mainly as an accompanying measure for tendon/ligament irritation, joint complaints, or general recovery support after intense training. Important to note: the evidence in humans is thin, and many claims are based on user experience rather than randomized studies.
Side Effects & Risks
- The data on long-term safety in humans is insufficient
- Local irritation at the injection site possible
- No standardized quality control on the gray market — purity and actual active content of available products often cannot be reliably verified
- Interactions with other medications are barely studied
Blood Work & Monitoring
There are no established, BPC-157-specific lab parameters for efficacy or safety monitoring. A general baseline blood panel before and during use makes sense, especially inflammatory markers (CRP) when used in a recovery context, along with medical consultation for existing conditions.
Harm-Reduction Notes
- Product quality is the biggest practical risk: consider only vendors with independent analysis certificates (HPLC/MS)
- Correct reconstitution with bacteriostatic water and sterile handling are essential (see peptide reconstitution calculator)
- Maintain cold-chain storage after reconstitution, limited shelf life
- With existing cancers or cancer risk, seek medical clarification, as angiogenic effects could theoretically be relevant
Legal status by region
Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.
| Region | Regulatory status |
|---|---|
| United States | Not approved for human useSold as a research chemical; marketing for human consumption is unlawful. |
| EU / UK | No marketing authorisationNeither a medicine nor a supplement — no legal route for human use. |
| Most other jurisdictions | Unregulated grey areaPossession is legal in many places precisely because no framework covers it. That is not an indication of safety. |
| Competitive sport | ProhibitedListed by WADA where a relevant class applies. |